Typhoid Fever
Conditions
Keywords
Typhoid, Typhoid conjugate vaccine, Cluster randomised trial
Brief summary
A cluster-randomised controlled Phase IV trial (cRCT) assessing the impact of a Vi-Polysaccharide conjugate vaccine in preventing typhoid infection in Asante Akim, Ghana (TyVEGHA) with a primary endpoint of determining the total protection conferred by single-dose vaccination with Vi-TT against blood culture-confirmed symptomatic S. Typhi infection in the intervention vaccine clusters, compared with the control vaccine clusters.
Detailed description
Typhoid fever remains a significant health problem in sub-Saharan Africa, with incidence rates \>100 cases per 100,000 person-years of observation. Despite the prequalification of safe and effective typhoid conjugate vaccines (TCV), the uptake of these vaccines in African countries has remained low. Real-life effectiveness data, which inform public health programs on the impact of TCVs in reducing typhoid-related mortality and morbidity, are critical to enhancing the introduction of TCVs in high-burden settings. Here we describe a cluster-randomized trial to investigate population-level protection of TCV against blood culture-confirmed typhoid fever. A total of 80 geographically distinct clusters have been delineated within the Agogo district of the Asante Akim region in Ghana. Clusters will be randomized to the intervention arm receiving TCV or a control arm receiving the meningococcal A conjugate vaccine. The primary study endpoint is the overall protection of TCV against blood culture-confirmed typhoid fever. Total, direct, and indirect protection will be measured as secondary outcomes. Blood culture-based enhanced surveillance will enable the estimation of incidence rates in the intervention and control clusters. Evaluation of the real-world impact of TCVs will improve uptake of prequalified/licensed safe and effective typhoid vaccines in public health programs of high burden settings.
Interventions
BIOLOGICALVi-TT
Single-dose V-TT administered to children and adolescents between the ages of 9 months to 15 years.
BIOLOGICALMCV-A vaccine
Single-dose of MCV-A vaccine (a meningococcal vaccine)
Sponsors
Kwame Nkrumah University of Science and Technology
University of Cambridge
International Centre for Diarrhoeal Disease Research, Bangladesh
Fondation Mérieux
University of Maryland, Baltimore
International Vaccine Institute
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Intervention model description
Participant- and observer-blinded, cluster-randomised controlled Phase IV trial
Eligibility
Sex/Gender
ALL
Age
9 Months to 15 Years
Healthy volunteers
Yes
Inclusion criteria
In order to be eligible to participate in this study, an individual must meet the following criteria: * Healthy participants aged 9 months to \<16 years (i.e., ≤15 years and 364 days) of age at the time of vaccination * Participants/Parents/legally authorized representative (LAR) who have voluntarily given informed assent (sought from participants aged 12 years to \<16 years) and informed consent * Participants/Parents/LAR living within study target area at the time of vaccination and willing to follow the study procedures and be available for the entire duration of the study
Exclusion criteria
An individual who meets any of the following criteria will be excluded from participation in this study: * Known allergy to any vaccine component * Self-reported ongoing acute and/or chronic illness * Any self-reported coagulopathies * Any medical or social compelling reasons in the judgment of a clinical physician * Self-reported pregnancy/Positive urine pregnancy test or lactating * Previous typhoid vaccination in the last 5 years (proven by the presentation of a vaccine card or self-reporting). Temporary
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Total Protection | 3 years | The incidence of blood culture-confirmed symptomatic TF in all vaccine recipients of the intervention clusters, compared with control clusters. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Overall protection | 3 years | The incidence of blood culture-confirmed symptomatic TF in all residents of the intervention clusters compared with that in all residents of control clusters |
| Total protection against severe typhoid. | 3 years | The incidence of severe TF in vaccinated individuals in intervention clusters compared to control clusters |
| Total protection against clinical typhoid. | 3 years | The incidence of clinical typhoid fever cases, defined as persistent fever (tympanic (≥38.0℃) or axillary temperature (≥37.5℃) or reported fever for ≥3 consecutive days) with abdominal complaints at a study surveillance site in vaccinated individuals in intervention clusters compared to control clusters. |
| Safety Assessment | 3 years | 1\) Proportion of adverse events in participants receiving Vi-TT compared with MCV-A, measured by: * The proportion of participants in each group of a sub-sample of the cohort developing adverse events/adverse reactions within the first 7 days post-vaccination. * The proportion of participants in each group of the cohort developing serious adverse events during the entire study period, as determined by self-reporting at follow-up contact. |
| Indirect Protection aganist Blood Culture Confirmed Typhoid. | 3 years | The incidence of blood culture-confirmed symptomatic TF in non-vaccinees of the intervention clusters compared with control clusters. |
| Seroconversion rates | 3 years | The seroconversion rates as measured by enzyme linked immunosorbent assay (anti-Vi IgM and IgG) for S. Typhi and iNTS at defined time points in a age-stratified subset of intervention and control vaccinees. |
| Geometric mean titers | 3 years | The antibody concentration as measured by enzyme linked immunosorbent assay (anti-Vi IgM and IgG) for S. Typhi and iNTS at defined time points in a age-stratified subset of intervention and control vaccinees. |
| Overall protection against clinical typhoid. | 3 years | The incidence of clinical typhoid fever cases presenting at a study surveillance site among all residents of the Vi-TT clusters compared to the control vaccine clusters. |
Countries
Ghana
Contacts
Primary ContactBirkneh T Tadesse, PhD
Backup ContactThaint Thaint Thwe, MBBS, MSc.
Outcome results
None listed